Diasorin SpAMIL:DIA +3.13%67 Net Margin % is 6.31% as of Dec. 2025, which is 70% below its 10-year median of 20.84. GuruFocus rates MIL:DIA with a GF Score™ of 67/100 and a GF Value™ of €90.07 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 204 Medical Diagnostics & Research companies, Diasorin SpA ranks better than 83.33% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Diasorin SpA's Net Income for the
three
months ended in Dec. 2025 was €19 Mil. Diasorin SpA's Revenue for the
three
months ended in Dec. 2025 was €295 Mil. Therefore, Diasorin SpA's net margin for the quarter that ended in Dec. 2025 was 6.31%.
The historical rank and industry rank for Diasorin SpA's Net Margin % or its related term are showing as below:
MIL:DIA'
s Net Margin % Range Over the Past 10 Years
Min: 12.16 Med: 20.84 Max: 28.13
Current: 12.16
MIL:DIA's Net Margin % is ranked better than 83.33% of 204
companies
in the Medical Diagnostics & Research industry
Industry Median: -2.405
vs MIL:DIA: 12.16
Diasorin SpA (MIL:DIA) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Diasorin SpA Net Margin % Related Terms
Diasorin SpA Net Margin % Historical Data
* Premium members only.
The historical data trend for Diasorin SpA's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MIL:DIA vs TMO, DHR, IDXX: Net Margin % Comparison
For the Diagnostics & Research subindustry, Diasorin SpA's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Diasorin SpA Net Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Diasorin SpA's Net Margin % distribution charts can be found below:
* The bar in red indicates where Diasorin SpA's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Diasorin SpA (MIL:DIA) has a Net Margin % of 6.31% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Diasorin SpA and its competitors. This is 70% below median its historical median of 20.84. Over the past decade, Diasorin SpA's Net Margin % has ranged from 12.16 to 28.13. According to the industry distribution chart, Diasorin SpA ranks #34 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 16.7%.
Is Diasorin SpA's Net Margin % too high?
Diasorin SpA's current Net Margin % of 6.31% is 70% below median its 10-year median of 20.84. Over the past 10 years, this metric has ranged from a low of 12.16 to a high of 28.13. Based on the distribution chart, Diasorin SpA ranks #34 out of 204 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Diasorin SpA has a GF Score™ of 67/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Diasorin SpA's Net Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Diasorin SpA ranks #34 out of 204 companies for Net Margin %. This places Diasorin SpA in the top 17% of its industry — outperforming the majority of peers. Historically, Diasorin SpA's own Net Margin % has ranged from 12.16 to 28.13 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Medical Diagnostics & Research company?
A good Net Margin % depends on the Medical Diagnostics & Research industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Diasorin SpA and its competitors. Diasorin SpA's current Net Margin % is 6.31%, which is 70% below median its own 10-year median of 20.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diasorin SpA stock overvalued right now?
Based on GuruFocus' analysis, Diasorin SpA (MIL:DIA) is currently considered Modestly Undervalued. The stock's GF Value™ is €90.07, compared to a current price of €66.48 — trading 26.2% below its estimated fair value. The current Net Margin % is 6.31%, which is 70% below median its 10-year median of 20.84. Diasorin SpA's overall GF Score™ is 67/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Diasorin SpA (MIL:DIA), the current Net Margin % is 6.31% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Diasorin SpA (MIL:DIA) Overvalued in 2026?
Based on GuruFocus' analysis, Diasorin SpA stock appears to be undervalued.
The current stock price of €66.48 is trading 26.2% below its estimated GF Value™ of €90.07.
GuruFocus considers Diasorin SpA to be Modestly Undervalued.
Key valuation signals for MIL:DIA:
Net Margin %: 6.31% (70% below median its 10-year median of 20.84)
GF Value™: €90.07 vs. price of €66.48 (26.2% below fair value)
No single metric tells the full story. See the MIL:DIA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Diasorin develops and manufactures a broad portfolio of in vitro diagnostics for detecting pathogens and sample contamination from the human body, as well as for use in industrial settings, such as food and water contamination testing. The company operates three segments: immunodiagnostics (69% of sales), molecular diagnostics (16%), and licensed technologies (14%). Diasorin was an important manufacturer of covid tests, which boosted its profits during the pandemic, but this segment's importance has decreased over the years, and in 2025, it accounted for only 1% of total sales.
67GF Score
Get the complete analysis for MIL:DIA
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:DIA has been successfully added to your 
